Identification of the Plant Compound Geraniin as a Novel Hsp90 Inhibitor

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Vassallo, Antonio ^a   Vaccaro, Maria Carmela ^b   De Tommasi, Nunziatina ^b   Dal Piaz, Fabrizio ^b   Leone, Antonella ^b  

^a UNIVERSITY OF BASILICATA   (Italy)

^b UNIVERSITY OF SALERNO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE; EPIDERMAL GROWTH FACTOR RECEPTOR; GERANIIN; HEAT SHOCK PROTEIN 90; PROTEIN KINASE B; RAF PROTEIN; TANESPIMYCIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING AFFINITY; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG IDENTIFICATION; DRUG PROTEIN BINDING; DRUG SCREENING; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL LINE; M PHASE CELL CYCLE CHECKPOINT; SURFACE PLASMON RESONANCE;

CELL CYCLE; GLUCOSIDES; HELA CELLS; HSP90 HEAT-SHOCK PROTEINS; HUMANS; HYDROLYZABLE TANNINS; JURKAT CELLS;

EID: 84884173540     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074266     Document Type: Article

References (37)

1. Pratt WB, Toft DO, (2003) Regulation of signaling protein function and trafficking by the hsp90/hsp70-based chaperone machinery. Exp Biol Med (Maywood) 228: 111-133.
2. Zhang H, Burrows F, (2004) Targeting multiple signal transduction pathways through inhibition of Hsp90. J Mol Med 82: 488-499 doi: 10.1007/s00109-004-0549-9.
3. Zhang T, Hamza A, Cao X, Wang B, Yu S, et al. (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol Cancer Ther 7: 162-170.
4. Whitesell L, Lindquist SL, (2005) HSP90 and the chaperoning of cancer. Nat Rev Cancer 5: 761-772 doi:10.1038/nrc1716.
5. Holzbeierlein JM, Windsperger A, Vielhauer G, (2010) Hsp90: a drug target? Curr Oncol Rep 12: 95-101 doi: 10.1007/s11912-010-0086-3.
6. Wang RE, (2011) Targeting heat shock proteins 70/90 and proteasome for cancer therapy. Curr Med Chem 18: 4250-4264.
7. Solit DB, Rosen N, (2006) Hsp90: a novel target for cancer therapy. Curr Top Med Chem 6: 1205-1214 doi: 10.2174/156802606777812068.
8. Trepel J, Mollapour M, Giaccone G, Neckers L, (2010) Targeting the dynamic Hsp90 complex in cancer. Nat Rev Cancer 10: 537-549 doi: 10.1038/nrc2887.
9. Piper PW, Millson SH, (2011) Mechanisms of resistance to Hsp90 inhibitor drugs: a complex mosaic emerges. Pharmaceuticals 4: 1400-1422 doi:10.3390/ph4111400.
10. Neckers L, Workman P, (2012) Hsp90 molecular chaperone inhibitors: are we there yet? Clin Cancer Res 18: 64-76.
11. Kummar S, Gutierrez ME, Gardner ER, Chen X, Figg WD, et al. (2010) Phase I trial of 17-dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG), a heat shock protein inhibitor, administered twice weekly in patients with advanced malignancies. Eur J Cancer 46: 340-347 doi: 10.1016/j.ejca.2009.10.026.
12. Heath EI, Hillman DW, Vaishampayan U, Sheng S, Sarkar F, et al. (2008) A phase II trial of 17-allylamino-17-demethoxygeldanamycin in patients with hormone-refractory metastatic prostate cancer. Clin Cancer Res 14: 7940-7946 doi: 10.1158/1078-0432.CCR-08-0221.
13. Yin Z, Henry EC, Gasiewicz TA, (2009) (-)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor. Biochemistry 48: 336-345 doi:10.1021/bi801637q.
14. Brandt GE, Schmidt MD, Prisinzano TE, Blagg BS, (2008) Gedunin, a novel hsp90 inhibitor: semisynthesis of derivatives and preliminary structure-activity relationships. J Med Chem 51: 6495-6502 doi: 10.1021/jm8007486.
15. Dal Piaz F, Vassallo A, Chini MG, Cordero FM, Cardona F, et al. (2012) Natural iminosugar (+)-lentiginosine inhibits ATPase and chaperone activity of hsp90. PLoS One 7: e43316 doi: 10.1371/journal.pone.0043316.
16. Oh SH, Woo JK, Yazici YD, Myers JN, Kim WY, et al. (2007) Structural basis for depletion of heat shock protein 90 client proteins by deguelin. J Natl Cancer Inst 99: 949-961 doi: 10.1093/jnci/djm007.
17. Okuda T, YoshidaT, Hatano T, (1995) Hydrolyzable tannins and related polyphenols. Fortschr Chem Org Naturst 66: 1-117.
18. Ito H, (2011) Metabolites of the ellagitannin geraniin and their antioxidant activities. Planta Med 77: 1110-1115 doi: 10.1055/s-0030-1270749.
19. Clifford MN, Scalbert A, (2000) Ellagitannins, occurrence in food, bioavailability and cancer prevention. J Food Sci Agric 80: 1118-1125.
20. Yang Y, Zhang L, Fan X, Qin C, Liu J, (2012) Antiviral effect of geraniin on human enterovirus 71 in vitro and in vivo. Bioorg Med Chem Lett 22: 2209-2211.
21. Lee JC, Tsai CY, Kao JY, Kao MC, Tsai SC, et al. (2008) Geraniin-mediated apoptosis by cleavage of focal adhesion kinase through up-regulation of Fas ligand expression in human melanoma cells. Mol Nutr Food Res 52: 655-663.
22. Dal Piaz F, Malafronte N, Romano A, Gallotta D, Belisario MA, et al. (2012) Structural characterization of tetranortriterpenes from Pseudrocedrela kotschyi and Trichilia emetica and study of their activity towards the chaperone Hsp90. Phytochemistry 75: 78-89 doi: 10.1016/j.phytochem.2011.12.002.
23. Dal Piaz F, Tosco A, Eletto D, Piccinelli AL, Moltedo O, et al. (2010) The identification of a novel natural activator of p300 histone acetyltranferase provides new insights into the modulation mechanism of this enzyme. ChemBioChem 11: 818-827 doi: 10.1002/cbic.200900721.
24. Mosmann T, (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63 doi: 10.1016/0022-1759(83)90303-4.
25. Jakob U, Lilie H, Meyer I, Buchner J, (1995) Transient interaction of Hsp90 with early unfolding intermediates of citrate synthase. J Biol Chem 270: 7288-7294.
26. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C, (1991) A rapid and simple method for measuring thymocite apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139: 271-279.
27. Cooper MA, (2003) Label-free screening of bio-molecular interactions. Anal Bioanal Chem 377: 834-842 doi: 10.1007/s00216-003-2111-y.
28. Faiella L, Dal Piaz F, Bisio A, Tosco A, De Tommasi N, (2012) A chemical proteomics approach reveals Hsp27 as a target for proapoptotic clerodane diterpenes. Mol Biosyst 8: 2637-2644 doi: 10.1039/c2mb25171j.
29. Orrù S, Dal Piaz F, Casbarra A, Biasol G, De Francesco R, et al. (1999) Conformational changes in the NS3 protease from hepatitis C virus strain Bk monitored by limited proteolysis and mass spectrometry. Protein Sci 8: 1445-1454 doi:10.1110/ps.8.7.1445.
30. Giommarelli C, Zuco V, Favini E, Pisano C, Dal Piaz F, et al. (2010) The enhancement of antiproliferative and proapoptotic activity of HDAC inhibitors by curcumin is mediated by Hsp90 inhibition. Cell Mol Life Sci 67: 995-1004 doi: 10.1007/s00018-009-0233-x.
31. Shelton SN, Shawgo ME, Matthews SB, Lu Y, Donnelly AC, et al. (2009) KU135, a novel novobiocin-derived C-terminal inhibitor of the 90-kDa heat shock protein, exerts potent antiproliferative effects in human leukemic cells. Mol Pharmacol 76: 13141322 doi: 10.1124/mol.109.058545.
32. Bisht KS, Bradbury CM, Mattson D, Kaushal A, Sowers A, et al. (2003) Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate the in vitro and in vivo radiation response of cervical tumor cells via the heat shock protein 90-mediated intracellular signaling and cytotoxicity. Cancer Res 63: 8984-8995.
33. Münster PN, Srethapakdi M, Moasser MM, Rosen N, (2001) Inhibition of heat shock protein 90 function by ansamycins causes the morphological and functional differentiation of breast cancer cells. Cancer Res. 61: 2945-2952.
34. Arlander SJ, Eapen AK, Vroman BT, McDonald RJ, Toft DO, Karnitz LM, (2003) Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress J Biol Chem. 278: 52572-52577.
35. Saif MW, Erlichman C, Dragovich T, Mendelson D, Toft D, et al. (2013) Open-label, dose-escalation, safety, pharmacokinetic, and pharmacodynamic study of intravenously administered CNF1010 (17-(allylamino)-17-demethoxygeldanamycin [17-AAG]) in patients with solid tumors. Cancer Chemother Pharmacol 71: 1345-1355. doi 10.1007/s00280-013-2134-9.
36. Cunningham CN, Krukenberg KA, Agard DA, (2008) Intra- and intermonomer interactions are required to synergistically facilitate ATP hydrolysis in Hsp90. J Biol Chem 283: 21170-21178.
37. Modi S, Stopeck AT, Gordon MS, Mendelson D, Solit DB, et al. (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study J Clin Oncol. 25: 5410-5417.